AstraZeneca (NASDAQ:AZN) Downgraded by Kepler Capital Markets

AstraZeneca (NASDAQ:AZNGet Rating) was downgraded by research analysts at Kepler Capital Markets from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday, The Fly reports.

Several other equities research analysts also recently weighed in on the stock. Deutsche Bank Aktiengesellschaft raised their target price on shares of AstraZeneca from £105 ($129.44) to £115 ($141.77) in a research note on Wednesday, April 6th. Barclays raised their price target on shares of AstraZeneca from £115 ($141.77) to £120 ($147.93) in a report on Thursday, April 14th. JPMorgan Chase & Co. raised their price target on shares of AstraZeneca from £100 ($123.27) to £120 ($147.93) in a report on Thursday, April 7th. DZ Bank raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Friday, February 11th. Finally, Credit Suisse Group raised their price target on shares of AstraZeneca from GBX 9,000 ($110.95) to £110 ($135.60) in a report on Friday, April 8th. Four analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $7,223.13.

AZN traded down $1.89 during trading on Wednesday, hitting $63.75. The stock had a trading volume of 321,546 shares, compared to its average volume of 7,749,243. The company has a market capitalization of $197.55 billion, a PE ratio of -199.21, a PEG ratio of 1.17 and a beta of 0.45. AstraZeneca has a twelve month low of $53.63 and a twelve month high of $71.70. The company has a debt-to-equity ratio of 0.72, a quick ratio of 0.76 and a current ratio of 1.16. The stock has a 50 day simple moving average of $65.65 and a two-hundred day simple moving average of $60.86.

AstraZeneca (NASDAQ:AZNGet Rating) last announced its earnings results on Friday, April 29th. The company reported $0.95 earnings per share for the quarter, beating the consensus estimate of $0.86 by $0.09. The company had revenue of $11.39 billion during the quarter, compared to the consensus estimate of $10.96 billion. AstraZeneca had a negative net margin of 2.56% and a positive return on equity of 26.29%. AstraZeneca’s revenue was up 55.6% compared to the same quarter last year. During the same period last year, the firm earned $0.81 earnings per share. On average, equities research analysts anticipate that AstraZeneca will post 3.34 EPS for the current year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. MayTech Global Investments LLC purchased a new position in shares of AstraZeneca in the third quarter valued at approximately $25,000. Arlington Partners LLC acquired a new stake in shares of AstraZeneca in the fourth quarter valued at approximately $25,000. Horan Securities Inc. acquired a new stake in shares of AstraZeneca in the fourth quarter valued at approximately $26,000. DB Wealth Management Group LLC acquired a new stake in shares of AstraZeneca in the first quarter valued at approximately $26,000. Finally, Parkside Financial Bank & Trust increased its holdings in shares of AstraZeneca by 4,875.0% in the first quarter. Parkside Financial Bank & Trust now owns 398 shares of the company’s stock valued at $26,000 after purchasing an additional 390 shares during the last quarter. Hedge funds and other institutional investors own 20.46% of the company’s stock.

About AstraZeneca (Get Rating)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

See Also

The Fly logo

Analyst Recommendations for AstraZeneca (NASDAQ:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.